Stimulant and Sedative Use Disorders: Clinical Management

1. Stimulant Use Disorders: Cocaine and Methamphetamine

Mechanism of Action and Neurobiological Effects

Cocaine and methamphetamine are powerful sympathomimetic agents that disrupt dopamine, norepinephrine, and serotonin homeostasis. Both inhibit monoamine reuptake: cocaine blocks dopamine, norepinephrine, and serotonin reuptake transporters with relatively equal potency; methamphetamine additionally causes reverse transport of these neurotransmitters through reuptake pumps, amplifying extracellular concentrations. Methamphetamine's duration of action (8-24 hours) far exceeds cocaine's (15-30 minutes), making it psychologically less reinforcing acutely but more conducive to binge use and sensitization.

The mesolimbic dopamine pathway (ventral tegmental area to nucleus accumbens) mediates the "rush" or rewarding effects. With repeated use, neuroadaptation occurs: downregulation of dopamine D2 receptors, blunting of the reward response to natural stimuli (food, sex, social interaction), and profound motivational dysregulation. Chronic stimulant use produces lasting changes in prefrontal cortex function, impairing executive decision-making, impulse control, and motivation for non-drug rewards.

Acute Intoxication and Sympathomimetic Toxidrome

Cocaine-Specific Complications

Cardiovascular Events: Cocaine uniquely causes coronary vasospasm by blocking norepinephrine reuptake at the sympathetic nerve terminals of coronary vessels, increasing systemic norepinephrine and causing alpha-adrenergic vasoconstriction. Myocardial infarction can occur even in young patients without atherosclerotic disease; chest pain is a common presentation. Myocarditis (direct cardiotoxicity) has also been documented. Aortic dissection is a known but rare complication. Management requires ECG, troponins, and close monitoring; nitrates and aspirin are appropriate, but beta-blockers are contraindicated due to unopposed alpha-adrenergic effects potentially worsening coronary spasm.

Intranasal Cocaine: Can cause perforation of nasal septum through vasoconstrictive ischemia and local tissue necrosis. Chronic use leads to nasal collapse and disfigurement.

Methamphetamine-Specific Complications

"Meth Mouth": Methamphetamine use causes severe dental deterioration through multiple mechanisms: xerostomia (reduced salivary flow), acidic environment from poor oral hygiene and consumption of sugary beverages, bruxism (teeth grinding), and direct neurotoxic effects on dental tissues.

Neurotoxicity and Dopamine System Damage: Chronic methamphetamine use produces persistent dopamine system damage: reduced D2 receptor availability on PET imaging, decreased dopamine transporter density, and profound anhedonia that persists for months after cessation. Some data suggest methamphetamine causes direct oxidative damage to dopamine neurons, potentially irreversible.

Stimulant Psychosis: Both cocaine and methamphetamine, particularly with chronic/high-dose use, can produce a state indistinguishable from paranoid schizophrenia: paranoid delusions, hallucinations (especially tactile — formication, the sensation of insects crawling on skin), organized thought disorder. This typically resolves within days to weeks of abstinence, distinguishing it from primary psychotic disorders. However, latent vulnerability to schizophrenia may be unmasked.

Stimulant Withdrawal and the Anhedonia Problem

Unlike opioid or alcohol withdrawal, stimulant withdrawal produces no life-threatening medical symptoms: no seizures, no autonomic hyperactivity, no delirium. However, psychological withdrawal is profound: severe dysphoria, anhedonia (inability to experience pleasure even from normally rewarding activities), fatigue, hypersomnia, anxiety, and intense craving. Many patients experience suicidal ideation during this phase. The "crash" typically lasts 9-12 hours after the last use, followed by a protracted withdrawal phase lasting days to weeks characterized by lower-grade dysphoria and craving.

This paradox makes stimulant addiction neurobiologically problematic: the drug is extremely reinforcing acutely, but withdrawal is so psychologically painful that relapse rates are extraordinarily high. Patients seeking to quit face a motivational landscape where all non-drug rewards are muted (anhedonia) and craving is intense.

Pharmacotherapy: The Absence of a Gold Standard

Unlike opioid use disorder (methadone, buprenorphine) or alcohol use disorder (naltrexone, acamprosate, disulfiram), no FDA-approved medication has demonstrated efficacy exceeding behavioral treatment for stimulant use disorder. Research has explored:

• Dopamine Agonists: Bromocriptine and amantadine have shown modest benefits in small trials but lack robust evidence. Theoretically, increasing dopamine signaling could reduce craving, but the evidence remains disappointing.
• Antidepressants: SSRIs (fluoxetine, sertraline, paroxetine) and bupropion have been studied; bupropion showed some promise (particularly for cocaine dependence with comorbid depression) but effect sizes are small.
• Modafinil: A wakefulness-promoting agent showing mixed results in cocaine dependence; may reduce craving in some patients but not consistently effective.
• Topiramate: Anticonvulsant with GABA-potentiating effects; showed promise in early trials for cocaine dependence but evidence is inconsistent.
• N-Acetylcysteine (NAC): An amino acid precursor to glutathione; emerging preclinical and early clinical evidence suggests NAC may reduce cue-induced craving through effects on glutamate neurotransmission and prefrontal cortex function. Not yet standard of care.

The lack of pharmacotherapy means behavioral intervention is the cornerstone of treatment.

Evidence-Based Behavioral Interventions: Contingency Management

Contingency Management (CM): The most robustly supported intervention for stimulant use disorders. CM leverages operant conditioning principles: patients receive tangible reinforcement (vouchers, prizes, cash) contingent on negative urine drug screens (UDS). The value of reinforcement is escalated with consecutive negative screens, then reset with any positive screen — creating strong incentives for abstinence while also immediately providing feedback.

Research consistently shows CM outperforms standard counseling for stimulant disorders. In comparative trials, CM + cognitive-behavioral therapy (CBT) produces 50-60% abstinence rates, compared to 20-30% with counseling alone. The effect size is large and reproducible. Mechanisms likely involve: (1) Immediate reinforcement of abstinence in the real world; (2) Restructuring the reward landscape to compete with drug reward; (3) Behavioral momentum — initial abstinence builds motivation to continue.

Practical implementation requires modest financial investment (~$10-15/day for a patient) but is cost-effective given addiction's societal cost. Limitations include: patient dropout, ethical concerns around payment for abstinence, and sustainability after the contingency period ends (relapse can increase when external reinforcement is withdrawn).

Cognitive-Behavioral Therapy and Relapse Prevention

CBT for substance use disorder focuses on functional analysis (understanding triggers and consequences), coping skills development, craving management, and relapse prevention. For stimulant users, CBT addresses the profound anhedonia: helping patients identify and engage in non-drug rewards, restructure thinking patterns around pleasure and motivation, and build cognitive flexibility in managing triggers.

Randomized trials show CBT + CM significantly outperforms either alone. Effect sizes are modest but clinically meaningful, with abstinence rates 50-70% vs. 20-30% controls. Duration matters: longer CBT (12+ weeks) produces better outcomes than brief interventions.

2. Sedative-Hypnotic Use Disorders: Beyond Benzodiazepines

Classes of Sedative-Hypnotics and Their Pharmacology

Sedative-hypnotic dependence encompasses benzodiazepines (alprazolam, diazepam, lorazepam), non-benzodiazepine hypnotics (Z-drugs: zopiclone, zolpidem, zaleplon), barbiturates (secobarbital, phenobarbital, pentobarbital), and other GABAergic agents (GHB, GBL). All share the mechanism of enhancing GABA-A receptor-mediated inhibitory neurotransmission in the CNS. Chronic use leads to neuroadaptation: reduced GABA-A receptor sensitivity, downregulation of inhibitory tone, upregulation of excitatory glutamatergic signaling.

Upon abrupt discontinuation, the brain is suddenly hyperexcitable: GABA inhibition is inadequate to restrain glutamate excitation, leading to seizures, autonomic hyperactivity, delirium, and potentially death.

Benzodiazepine Withdrawal Syndrome

Onset and Duration: Withdrawal timeline depends on benzodiazepine half-life. Short-acting agents (alprazolam, triazolam) produce symptoms within 12-24 hours; long-acting agents (diazepam, chlordiazepoxide) may not present until 5-7 days post-discontinuation. Duration can extend 2-4 weeks (protracted withdrawal).

Clinical Presentation (Mild to Severe):

• Stage 1 (Mild): Anxiety, tremor, diaphoresis, insomnia, muscle aches, nausea
• Stage 2 (Moderate): Hallucinations (visual/tactile), psychomotor agitation, tachycardia, hyperreflexia
• Stage 3 (Severe): Generalized tonic-clonic seizures (1-4% of high-dose chronic users), delirium, autonomic hyperactivity (dangerous hypertension and tachycardia), hyperthermia, rhabdomyolysis

Risk factors for severe withdrawal include: high-dose chronic use, short-acting agents, abrupt discontinuation, comorbid alcohol use disorder (synergistic GABA-A depression), medical comorbidities.

Benzodiazepine Tapering Protocol

Safe withdrawal requires a slow taper, typically over 8-12 weeks. General principles:

Step 1: Convert to Long-Acting Equivalents. Patients on short-acting benzodiazepines (alprazolam, lorazepam) are converted to diazepam (or phenobarbital for medically complex patients). This provides a longer half-life, making the taper more gradual and reducing seizure risk. Conversion tables exist; approximate alprazolam 1 mg = diazepam 5-10 mg.

Step 2: Establish Baseline Dose. Determine total daily benzodiazepine dose and convert to diazepam equivalents.

Step 3: Reduce by 10-25% Every 3-7 Days. A typical schedule reduces dose weekly by 2-5 mg of diazepam. Example for a patient on 40 mg diazepam daily: Week 1-2: 40 mg → Week 3: 35-38 mg → Week 4: 30-33 mg, etc. Slower reductions (~10% weekly) reduce withdrawal severity; faster reductions (>25%) risk breakthrough symptoms and seizures. Many patients require even slower tapers (20-40 weeks).

Step 4: Monitor for Withdrawal Symptoms. If mild withdrawal emerges (increased anxiety, tremor, insomnia), pause the taper for 1-2 weeks before continuing. If moderate symptoms develop, increase the dose by 25% and slow the taper.

Step 5: Managing Breakthrough Symptoms. During tapering, adjunctive medications can support comfort: hydroxyzine (50-100 mg TID) for anxiety, trazodone (50-100 mg) for insomnia, propranolol (40-80 mg) for tremor and autonomic symptoms. Some protocols use buspirone (15 mg TID) for anxiety, but it is less effective acutely than benzodiazepines.

Inpatient vs. Outpatient Tapering: High-dose chronic users or medically unstable patients should undergo inpatient withdrawal with continuous monitoring, IV fluids, ICU-level care for seizures. Outpatient tapers are appropriate for moderate-dose users with good social support and no contraindications.

Barbiturate and Z-Drug Withdrawal

Barbiturates (Secobarbital, Pentobarbital, Phenobarbital): Long-acting barbiturates (phenobarbital, >20 hr half-life) are safer to withdraw from than short-acting (secobarbital, pentobarbital, <2-8 hr). Short-acting barbiturate withdrawal mimics alcohol withdrawal: autonomic hyperactivity, seizures, hallucinations, delirium, potential death. Management involves converting to long-acting phenobarbital and tapering slowly (similar to benzodiazepine protocols). Initial phenobarbital loading may be needed: 100-200 mg IV/IM, then tapered by 10% daily (longer if unstable).

Z-Drugs (Zolpidem, Zopiclone, Zaleplon): Despite marketing as "safer" hypnotics without benzodiazepine-like dependence potential, Z-drugs produce equivalent physical and psychological dependence with chronic use. Withdrawal is less severe than benzodiazepines but still includes insomnia, anxiety, tremor, and rarely seizures. Tapering by 25% every 2-3 days is generally safe; abrupt discontinuation can produce rebound insomnia and mild withdrawal symptoms.

GHB (Gamma-Hydroxybutyrate) and GBL (Gamma-Butyrolactone)

GHB is a short-chain fatty acid with dual action: GABA-B agonism and GHB-specific receptor activation. GBL is a prodrug metabolized to GHB. Both have acquired street use and are increasingly encountered in addiction medicine; GHB withdrawal is distinctive and medically severe.

Withdrawal Syndrome: Onset rapid (within 1-12 hours post-last dose given GHB's short half-life, 20-30 minutes). Clinical features: extreme insomnia (refractory to sedatives), autonomic hyperactivity (hypertension, tachycardia, fever), tremor, confusion, psychomotor agitation, hallucinations. Seizures are possible but rare. A distinctive feature is profound insomnia: patients may not sleep for 3-5 days despite aggressive sedation attempts. Delirium and psychiatric symptoms (paranoia, aggression) are common. Duration typically 3-14 days depending on dose and duration of use.

Management: High-dose benzodiazepines are the cornerstone (lorazepam 2-4 mg IV q4h or higher; some patients require 80-120 mg/day during peak withdrawal). Baclofen (GABA-B agonist) shows some promise in managing withdrawal severity, potentially through maintenance of GABA-B tone. Barbiturates (phenobarbital) are an alternative for benzodiazepine-refractory cases. Supportive care with ICU monitoring is often necessary. Unlike benzodiazepine withdrawal, no taper is possible (GHB must be discontinued abruptly); management is symptomatic support during the acute withdrawal period.

3. Hallucinogen-Related Disorders

Hallucinogen-Persisting Perceptual Disorder (HPPD)

HPPD is a state of persistent visual disturbances (halos around lights, trails behind moving objects, visual snow, color intensity changes) following hallucinogen use, persisting after acute drug effects have resolved. Onset can be immediate (during/after use) or delayed (days to months later). Typically follows LSD, psilocybin, or MDMA use; dissociative agents (ketamine, dextromethorphan) can also cause HPPD-like symptoms. Prevalence is estimated 4-5% among hallucinogen users.

Neuroimaging in HPPD shows altered visual cortex connectivity and hyperexcitability. Mechanisms are incompletely understood but likely involve persistent alterations in 5-HT2A receptor function and visual gating mechanisms. Spontaneous resolution occurs in ~50% of cases within weeks to months; others experience chronic symptoms. Management is primarily reassurance, avoiding triggers (stress, fatigue, certain foods), and symptomatic treatment. Some clinicians report benefit with SSRIs or benzodiazepines (lorazepam, clonazepam), though evidence is limited. Lamotrigine has theoretical appeal (glutamate modulation, visual system effects) but evidence is anecdotal.

Hallucinogen-Related Acute Psychological Reactions

"Bad trips" are acute anxiety, panic, paranoia, or transient psychosis occurring during or shortly after hallucinogen use. Typically self-limited (resolution within 4-12 hours) but psychologically severe and requiring crisis intervention. Risk factors include predisposition to anxiety disorders, prior trauma, unfamiliar or hostile environment ("set and setting"), and high doses.

Management is non-pharmacological: calm reassurance, "talking down," safe physical environment, reduction of stimulation. Benzodiazepines (lorazepam 1-2 mg) can be offered for severe anxiety; antipsychotics are generally avoided (can worsen dysphoria paradoxically and may stigmatize with "forced medical treatment" narrative). Most bad trips resolve without intervention with time.

Dissociative vs. Serotonergic Hallucinogens

Serotonergic hallucinogens (LSD, psilocybin, mescaline) primarily act as partial agonists at 5-HT2A receptors in the cortex. Dissociative agents (ketamine, dextromethorphan, phencyclidine) are NMDA receptor antagonists, producing a distinct phenomenology: out-of-body experiences, time dilation, emotional numbing alongside visual hallucinations. Dissociative intoxication carries higher medical risk (accidental injury, impaired judgment, rhabdomyolysis from exertion). Acute dissociative intoxication may require benzodiazepines and medical monitoring for complications.

Therapeutic Use of Psychedelics: Emerging Evidence

Despite decades of legal prohibition, rigorous clinical research in psychedelic-assisted therapy has resumed. Psilocybin-assisted psychotherapy shows promising results in treatment-resistant depression (Phase II trials showing ~70% response rates vs. 20% controls), end-of-life anxiety in terminal cancer patients, and PTSD. LSD-assisted psychotherapy shows benefit in anxiety. MDMA-assisted therapy demonstrates efficacy in PTSD. These therapies employ structured protocols: psychotherapy preparation, guided psychedelic session in a supportive environment, and integration psychotherapy. FDA breakthrough designation has been granted for psilocybin in treatment-resistant depression and MDMA in PTSD.

4. Inhalant Use Disorders and Synthetic Drugs

Inhalant Neurotoxicity: Toluene and Nitrous Oxide

Inhalants (glue, paint thinner, nitrous oxide) produce acute intoxication through CNS depression, but chronic use causes severe, often irreversible neurotoxicity. Toluene (solvent in glues and paints) produces acute euphoria but chronic exposure causes cerebellar atrophy, peripheral neuropathy, cognitive impairment, and white matter changes. Nitrous oxide (laughing gas) blocks B12 metabolism through inactivation of methionine synthase; chronic use leads to B12 deficiency manifesting as subacute combined degeneration: posterior column syndrome (paresthesias, loss of proprioception and vibration sense, gait ataxia), peripheral neuropathy, and cognitive decline. Unlike other withdrawals, inhalants produce no significant withdrawal syndrome upon discontinuation, but neurological damage may be permanent.

Synthetic Cathinones ("Bath Salts") and Synthetic Cannabinoids

Synthetic cathinones (methylone, MDPV, mephedrone) are analogs of cathine (naturally occurring alkaloid in khat plant) designed to evade legal restrictions. They produce potent sympathomimetic effects exceeding cocaine: severe agitation, psychosis, violent behavior, and cardiovascular emergencies (myocardial infarction, sudden cardiac death). Synthetic cannabinoids (K2, Spice) are full agonists at CB1 receptors (cannabis is a partial agonist), producing more severe psychosis, severe anxiety, and physical dependence. Acute intoxication management resembles cocaine toxicity; no specific antidotes exist. Withdrawal from synthetic cannabinoids produces dysphoria and craving similar to cannabis but more severe. Treatment is supportive care and behavioral intervention.

5. General Principles of Substance Use Treatment

Effective substance use disorder treatment integrates biomedical, behavioral, and social approaches:

• Pharmacotherapy (Where Available): Methadone or buprenorphine for opioid use disorder, naltrexone for alcohol use disorder, benzodiazepine tapers for sedative dependence. Psychotropic medications for comorbid psychiatric disorders.
• Behavioral Intervention: Contingency management and cognitive-behavioral therapy are evidence-based and should be offered whenever possible.
• Peer Support: 12-step programs, SMART Recovery, and other mutual aid societies provide social support and structure; effective for many patients.
• Integrated Dual-Diagnosis Treatment: Substance use is rarely isolated; concurrent depression, anxiety, PTSD, bipolar disorder require simultaneous treatment. Psychiatry and addiction medicine must coordinate.
• Relapse Prevention and Planning: Identification of high-risk situations, coping strategies, and a plan for managing lapses without full relapse.
• Social Reintegration: Employment, stable housing, family reconnection, and meaningful activity are protective factors. Recovery is not abstinence alone but rebuilding a life.